Publications by authors named "Jurriaan Janssen"
Next Generation Sequencing-based subtyping and interim- and end of treatment positron emission tomography (i/eot-PET) monitoring have high potential for upfront and on-treatment risk assessment of diffuse large B-cell lymphoma patients. We performed Dana Farber Cancer Institute (DFCI) and LymphGen genetic subtyping for the HOVON84 (n = 208, EudraCT-2006-005174-42) and PETAL (n = 204, EudraCT-2006-001641-33) trials retrospectively combined with DFCI genetic data (n = 304). For all R-CHOP treated patients (n = 592), C5/MCD- and C2/A53-subtypes show significantly worse outcome independent of the international prognostic index.
View Article and Find Full Text PDFArticle Synopsis
- - ABC-DLBCL is a subtype of diffuse large B cell lymphoma that shows constant B cell receptor (BCR) signaling and NF-κB activation, often due to specific mutations in BCR signaling pathways in a few cases.
- - In a study, it was found that many DLBCL-derived BCRs can stimulate changes in BCR signaling independently, even without external activation, similar to mechanisms seen in chronic lymphocytic leukemia (CLL).
- - This autonomous signaling is linked to specific immunoglobulin M (IgM) types and unique sequences in the BCR, mainly occurring in non-germinal center B cell (non-GCB) types of DLBCL, suggesting a new way to classify this cancer